Log in

Delcath Systems Stock Price, Forecast & Analysis (OTCMKTS:DCTHD)

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Volume12,654 shs
Average Volume79,871 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Delcath Systems, Inc is a late-stage clinical development company with early commercial activity in Europe focused on cancers of the liver. The Company is a specialty pharmaceutical and medical device company developing its product, Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS). The Company's system delivers and filters melphalan hydrochloride, which is marketed as a device under the trade name Delcath Hepatic CHEMOSAT Delivery System for Melphalan (CHEMOSAT). Read More…

Industry, Sector and Symbol

Industry Surgical & medical instruments
Previous SymbolNASDAQ:DCTH



Sales & Book Value

Annual SalesN/A



Next Earnings DateN/A
OptionableNot Optionable

Receive DCTHD News and Ratings via Email

Sign-up to receive the latest news and ratings for DCTHD and its competitors with MarketBeat's FREE daily newsletter.

Delcath Systems (OTCMKTS:DCTHD) Frequently Asked Questions

What is Delcath Systems' stock symbol?

Delcath Systems trades on the OTCMKTS under the ticker symbol "DCTHD."

When did Delcath Systems' stock split? How did Delcath Systems' stock split work?

Delcath Systems shares reverse split on the morning of Monday, November 6th 2017. The 1-350 reverse split was announced on Friday, November 3rd 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, November 3rd 2017. An investor that had 100 shares of Delcath Systems stock prior to the reverse split would have 0 shares after the split.

How were Delcath Systems' earnings last quarter?

Delcath Systems, Inc. (OTCMKTS:DCTHD) announced its quarterly earnings results on Friday, November, 11th. The medical device company reported ($231.00) earnings per share for the quarter, beating the consensus estimate of ($1,151.50) by $920.50. The medical device company earned $0.44 million during the quarter. During the same period in the prior year, the firm earned ($686.00) earnings per share. View Delcath Systems' Earnings History.

Has Delcath Systems been receiving favorable news coverage?

News headlines about DCTHD stock have been trending extremely negative on Tuesday, according to InfoTrie. The research firm identifies negative and positive media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Delcath Systems earned a media sentiment score of -4.6 on InfoTrie's scale. They also gave media coverage about the medical device company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for Delcath Systems.

Who are some of Delcath Systems' key competitors?

What other stocks do shareholders of Delcath Systems own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Delcath Systems investors own include CytRx (CYTR), Dendreon (DNDNQ), DryShips (drys), Rexahn Pharmaceuticals (REXN), VirnetX (VHC), Reshape Lifesciences (RSLS), TOP SHIPS (TOPS), Inovio Pharmaceuticals (INO), Cassava Sciences (SAVA) and ZIOPHARM Oncology (ZIOP).

Who are Delcath Systems' key executives?

Delcath Systems' management team includes the folowing people:
  • Roger G. Stoll Ph.D., Chairman of the Board (Age 74)
  • Jennifer K. Simpson Ph.D., President, Chief Executive Officer, Director (Age 48)
  • Barbra C. Keck, Chief Financial Officer, Secretary (Age 39)
  • John Purpura, Executive Vice President - Global Head of Operations (Age 55)
  • Simon C. Pedder Ph.D., Director (Age 56)
  • William Dodge Rueckert, Independent Director (Age 64)
  • Marco Taglietti M.D., Independent Director (Age 57)

What is Delcath Systems' official website?

The official website for Delcath Systems is http://www.delcath.com/.

How can I contact Delcath Systems?

Delcath Systems' mailing address is 1633 BROADWAY SUITE 22C, NEW YORK NY, 10019. The medical device company can be reached via phone at 212-489-2100 or via email at [email protected]

MarketBeat Community Rating for Delcath Systems (OTCMKTS DCTHD)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  204 (Vote Outperform)
Underperform Votes:  201 (Vote Underperform)
Total Votes:  405
MarketBeat's community ratings are surveys of what our community members think about Delcath Systems and other stocks. Vote "Outperform" if you believe DCTHD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DCTHD will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/19/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel